Changes in Myocardial Iron After Iron Administration

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

53 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-01

Study Completion Date

2018-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Recent studies have shown that treatment with intravenous iron in patients with iron deficiency (ID) and heart failure with reduced ejection fraction (HFrEF) improves symptomatology, functional capacity, quality of life, and decreases hospitalizations regardless of anemia. In addition, a decrease in myocardial iron content has been observed in patients with chronic HFrEF. This preliminary evidence has led to postulate that myocardial iron deficiency could play a direct role in the pathogenesis and progression of the disease.

The investigators hypothesize that the repletion of myocardial iron would explain part of the benefit of this treatment. Thus, the investigators postulate that cardiac magnetic resonance (CMR) (T2\* and T1-mapping sequences) will be sensible enough to detect changes in myocardial iron content as a result of intravenous iron administration, and that such changes will correlate with simultaneous changes in parameters of heart failure severity.

In this double-blind 1:1 randomized study controlled by placebo the investigators aim to determine the changes in myocardial iron content after treatment with intravenous ferric carboxymaltose (FCM) by CMR at 7 and 30 days in patients with stable HFrEF and ID.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ferric Carboximaltose on Intra-myocardial Iron Load in Patients With Heart Failure

NCT03871699

Cardiac Failure Systolic Heart Failure Heart Failure, Systolic

UNKNOWN PHASE4

Impact of Iron Deficiency on Arrhythmic Events and Resting ECG Abnormalities in Patients Hospitalized With Heart Failure

NCT07277140

Heart Failure Iron Deficiency

NOT_YET_RECRUITING

Study of the Prevalence of Iron Deficiency in Patients With Heart Failure

NCT03924258

Heart Failure

UNKNOWN NA

Iron Deficiency in Patients With Heart Failure and Reduced and Mildly Reduced Ejection Fraction

NCT05992116

Iron Deficiency Heart Failure With Reduced Ejection Fraction Heart Failure With Mildly Reduced Ejection Fraction

COMPLETED

Impact of Iron Deficiency and Its Correction on Mitochondrial Metabolism of the Cardiomyocyte (MitoCardioFer)

NCT03541213

Iron-deficiency Valvular Heart Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure Iron-deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

After providing informed consent, patients will be randomly assigned, with a remote, web-based computer-generated block randomization procedure in an allocation 1:1 ratio, to either receive intravenous ferric carboxymaltose (FCM) or placebo. Intramyocardial iron will be evaluated at 3 time points: before administration of CMF/placebo, and at 7 and 30 days. At 30 days, patients assigned to placebo will receive intravenous CMF if iron deficiency persists.

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Because ferric carboxymaltose is a dark-brown solution that is easily distinguishable from the saline placebo, study personnel responsible for the preparation and administration of the study drug will aware of the group assignments and therefore, not involved in any study assessments. To ensure that patients will be unaware of the study drug, materials used in drug administration will be covered with aluminum foil or other opaque material and the injection site shield from the patient view. Once treatment is allocated, the investigators team will ensure that patients are blinded to the treatment received.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intravenous ferric carboxymaltose

Ferric Carboxymaltose solution \[Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)\] will be given as a perfusion of 20 mL (which is the amount of FCM that is equivalent to 1000 mg of iron) diluted in a sterile saline solution (0.9% weight/volume (w/v) NaCl) administered over at least 15 min.

Group Type ACTIVE_COMPARATOR

Ferric carboymaltose

Intervention Type DRUG

Ferric Carboxymaltose solution \[Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)\]

Cardiac magnetic resonance

Intervention Type DIAGNOSTIC_TEST

Cardiac magnetic resonance including T2\* and T1-mapping sequences

Normal saline

Normal saline (0.9% weight/volume (w/v) NaCl) administered as per the instructions for active therapy.

Group Type PLACEBO_COMPARATOR

Placebo (Normal saline)

Intervention Type DRUG

Normal saline (0.9% weight/volume (w/v) NaCl)

Cardiac magnetic resonance

Intervention Type DIAGNOSTIC_TEST

Cardiac magnetic resonance including T2\* and T1-mapping sequences

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ferric carboymaltose

Ferric Carboxymaltose solution \[Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)\]

Intervention Type DRUG

Placebo (Normal saline)

Normal saline (0.9% weight/volume (w/v) NaCl)

Intervention Type DRUG

Cardiac magnetic resonance

Cardiac magnetic resonance including T2\* and T1-mapping sequences

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ferinject, intravenous iron

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with ambulatory chronic heart failure
* Older than 18 years
* Patients in NYHA class II-III on optimal background therapy (as determined by the investigator) for at least 4 weeks with no dose changes of HF drugs during the last 2 weeks (with the exception of diuretics)
* Elevated natriuretic peptides levels (NT-proBNP \>400 pg/ml) at the screening visit
* Left ventricle ejection fraction \<50% documented in the last 12 months
* Iron deficiency defined as: serum ferritin level \<100 μg/L or ferritin level 100-299 μg/L when TSAT is less than 20%, and hemoglobin \<15 g/dL (all at screening)
* Participant is willing and able to give informed consent for participation in the study

Exclusion Criteria

* Known sensitivity to any of the products to be administered per protocol.
* History of acquired iron overload.
* Severe valve disease, or being scheduled for cardiac surgery within the next 30 days.
* Acute myocardial infarction or acute coronary syndrome, transient ischemic attack, or stroke within the last 3 months prior to randomization.
* Coronary artery bypass graft, percutaneous intervention (e.g. cardiac, cerebrovascular, and aortic; diagnostic catheters are allowed), or major surgery, including thoracic and cardiac surgery, within the last 3 months prior to randomization.
* Ischemic heart disease scheduled for revascularization procedures within the next 30 days.
* HF scheduled for cardiac resynchronization therapy within the next 30 days.
* Patients with active bleeding in the last 30 days.
* Known active infection or active malignancy.
* Subject at an immediate need of transfusion or hemoglobin ≥15 g/dL.
* Anemia due to reasons other than iron deficiency
* Immunosuppressive therapy or renal dialysis
* History of erythropoietin, intravenous iron therapy, and blood transfusion in the previous 12 weeks.
* Oral iron therapy at doses \>100 mg/day in previous 1 week prior to randomization.
* Subjects with an immediate need for transfusion.
* Pregnant or breastfeeding women.
* Subject of childbearing potential who is not willing to use adequate contraceptive precautions during the study and for up to 5 days after the last scheduled dose of study medication.
* Subject currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study, or subject is receiving other investigational agent(s).
* Any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No